Sunday

Alcohol and other Drugs in a Public Health Context. ROBIN ROOM.

Alcohol and other Drugs in a Public Health Context. ROBIN ROOM. 
        Encyclopedia of Bioethics. Ed. Stephen Post. Vol. 1. 3rd ed. New York: Macmillan Reference USA, 2004. p137-144. 5 vols. 

Full Text: COPYRIGHT 2004 Macmillan Reference USA, COPYRIGHT 2006 Thomson Gale, a part of The Thomson Corporation

Page 137

ALCOHOL AND OTHER DRUGS IN A PUBLIC HEALTH CONTEXT

•••

Psychoactive drugs are substances that alter the mental state of humans after ingestion. There are a wide variety of those substances, both naturally occurring and synthesized, including tobacco, alcoholic beverages, coffee, tea, chocolate, and some spices, as well as substances that are legally available only through medical channels, such as benzodiazepides, cannabinols, opiates, and cocaine. Such substances often have other use values along with their psychoactive properties. Users may like the taste or the image of themselves that the use of those substances conveys. Substance use may be a medium of sociability (Partanen) or part of a religious ritual. Some substances have other useful properties; alcohol, for example, is a source of calories and is used as a solvent in many tinctures.

Psychoactive drugs differ in their metabolic pathways and mechanisms of action in the human body, the strength of their effects, and the states of mind and feelings they induce. However, the effects of drug use also are highly dependent on the pattern of use and on the set and setting, that is, the expectations of the user and of others who are present and the context of use (Zinberg). Although the psychoactive effect of tobacco may not register in the consciousness of a habituated cigarette smoker, in other circumstances the effect of tobacco use may be so strong that the user is rendered unconscious, as early Spanish observers reported in describing tobacco use among native South Americans (Robicsek).

Psychoactive substances frequently are valued by potential consumers well above the cost of production. On the onePage 138 | Top of Article hand, this means that taxes on alcohol, tobacco, and other drugs have long been an important fiscal resource for the state. On the other hand, it means that there are substantial incentives for an illicit market to emerge in places where the sale of drugs is forbidden or stringently restricted.

A consideration of drugs in a public health context may start with an examination of general cultural patternings and understandings of drug use. This entry continues by discussing the major approaches to limiting harm from drug use. The entry concludes with a characterization of the major directions in the development of drug policies in the United States and other industrialized countries.

General Cultural Framings of Drug Abuse

Three social patternings of psychoactive drug use can be distinguished as prototypical: medicinal use, customary regular use, and intermittent use. In many traditional societies some drugs or formulations have been confined to medicinal use, that is, use under the supervision of a healer to alleviate mental or physical illness or distress. For several centuries after the technique for distilling alcoholic spirits had diffused from China through the Arab world to Europe, for instance, spirits-based drinks were regarded primarily as medicines (Wasson). This way of framing drug use has been routinized in the modern state through a prescription system, with physicians writing the prescriptions and pharmacists filling them. Drugs included in the prescription system usually are forbidden for nonmedicinal use.

When a drug becomes a regular accompaniment of everyday life, its psychoactivity often is muted and even unnoticed, as is often the case for a habitual cigarette smoker. Similarly, in southern European wine cultures wine is differentiated from intoxicating "alcohol"; wine drinkers are expected to maintain their original comportment after drinking. This may be called a pattern of banalized use: A potentially powerful psychoactive agent is domesticated into a mundane article of daily life that is available relatively freely in the consumer market.

Intermittent use—for instance, on sacred occasions, at festivals, or only on weekends—minimizes the buildup of tolerance to a drug. It is in the context of those patterns that the greatest attention is likely to be paid to a drug's psychoactive properties. The drug may be understood by both the user and others as having taken control of the user's behavior and thus to explain otherwise unexpected behavior, whether bad or good (see the "disinhibition hypothesis" in Pernanen; see also Room, 2001b). As in Robert Louis Stevenson's fable of Jekyll and Hyde, normal self-control is expected to return when the effects of the drug wear off. In light of the power attributed to the substance, access to it may be limited: in traditional societies by sumptuary rules keyed to social differentiations and in industrial societies by other forms of market restriction.

In industrial societies a fourth pattern of use is commonly recognized for certain drugs: addicted or dependent use that is marked by regular use, often of large doses. Because the pattern of use of a particular drug is not defined in the society as banalized, addiction is defined as an individual failing rather than a social pattern. Although attention is paid to physical factors that sustain regular use, such as use to relieve withdrawal symptoms, most formulations of addiction focus on psychological aspects, including an apparent commitment to drug use to the exclusion of other activities and despite default in performing major social roles. An addiction concept thus also focuses on the loss of normal self-control, but the emphasis is not so much on the immediate effects of the drug as it is on a repeated or continuing pattern of an apparent inability to control or refrain from use despite the adverse consequences.

Addiction as a Modern Governing Image

The concept of addiction as an affliction of habituated drug users first arose in its modern form for alcohol as heavy drinking lost its banalized status in the United States and some other countries under the influence of the temperance movement of the nineteenth century (Levine; Valverde). Habitual drunkenness had been viewed since the Middle Ages as a subclass of gluttony; now abstinence from alcohol was singled out as a separate virtue and an important sign of the key virtue in a democracy of autonomous citizens: self- control. Along with other mental disorders, chronic inebriety, as alcohol addiction usually was termed, was reinterpreted as a disease suitable for medical intervention, although without losing all of its negative moral loading.

In nineteenth-century formulations addictiveness was seen as an inherent property of alcohol no matter who used it, and that perception justified efforts to prohibit its sale. By the late nineteenth century such addiction concepts were being applied also to opiates and other drugs, and this formulation has remained the governing image (Room, 2001a) for those drugs to the present day. However, as temperance became unpopular with the repeal of national alcohol prohibition in the United States in 1933, for alcohol the concept was reformulated to be a property of the individual "alcoholic," who was mysteriously unable to drink like a normal drinker. This "disease concept of alcoholism" received its classic scholarly formulation by Jellinek(1952), although that author (1960) later retreated to a broader formulation of alcohol problems.

Page 139 | Top of Article

In popular thinking and often in official definitions addiction has remained a property of the drug for illicit drugs but of the person for alcohol (Christie and Bruun). The inherent addictiveness attributed to illicit drugs is the primary rationale for their prohibition. The extent of the anathema imposed in U.S. cultural politics by labeling a substance as addictive can be gauged from the unanimous testimony of cigarette company executives to the U.S. Congress in 1994 that they did not believe that cigarettes are addictive despite the evidence of their own corporate research (Hilts).

In recent years philosophers and cultural analysts have begun to question and rethink the meaning of addiction concepts (Szasz; Fingarette; Keane) and consider the implications for drug policy (Husak). In a related initiative economists have begun propounding and testing theories of rational addiction (Elster and Skog). By the early 2000s that critical thinking had had no discernible influence on the American political consensus in favor of an addiction-based policy for illicit drugs.

Approaches to Limiting the Problems from Drug Use

Most human societies have known of and used psychoactive drugs, and most also have made efforts to limit the use of one or more drugs, customarily if not legislatively. Historically, the main aim of those restrictions was to diminish threats to the social order or to increase the labor supply. Public health concerns sometimes were expressed in attempts to justify restrictions—for instance, in the efforts of James I of England to stem tobacco smoking (Austin)—but such concerns were rarely decisive. The restrictions on the spirits market adopted in Britain as a response to the extreme alcoholization of eighteenth-century London (depicted in Hogarth's famous print of "Gin Lane") are an early example of limits substantially motivated by concern about public health (Warner; Dillon). Only in recent decades have public health concerns become a major element in discussions of drug policies, although those concerns often are subordinated in the case of legal drugs to fiscal and economic considerations and in the case of illicit drugs to moral and lifestyle issues.

Health hazards from psychoactive drugs occur in two main ways: in connection with particular occasions of use and in connection with the patterning of use over time. Thus, an overdose from barbiturates, a traffic casualty from drunk driving, and an HIV infection from sharing a needle to inject heroin are all consequences associated with a particular occasion of use, whereas lung cancer from tobacco smoking, liver cirrhosis from alcohol use, and (by definition) addiction all reflect a history of heavy use (Room, 1985). As is discussed below, measures to prevent event-related problems often differ from and even conflict with measures to prevent cumulative, condition-related problems. For alcohol the ethical situation with regard to public health measures is complicated by the possibility of a protective effect of drinking on heart disease that must be balanced against the undoubted negative health effects (Room, 2001c; Rehm et al.).

Efforts to limit problems from drug use can be seen as oriented to controlling whether a drug is used at all; influencing the amount, context, and pattern of use; or preventing harmful consequences of use (Bruun; Moore and Gerstein).

PROHIBITING USE TO ALL OR SOME. Efforts to impose a general prohibition on the use of a drug for all the members of a society have a lengthy history, although those efforts frequently have failed (Austin). Perhaps the most sustained effort has been the prohibition on alcoholic beverages in Islamic societies. In general, religious taboos on drug use tend to have had more lasting effect than have state prohibitions. Prohibiting the sale or use of a drug that some might choose to use and enjoy involves a degree of intervention in the marketplace and in private behavior that is unusual in modern democratic states. If there are people who use a drug without problems, the prohibition on their use of that drug must be justified as benefiting others who would have or would cause problems if they used it. In societies with a strong tradition of individual liberties and consumer sovereignty discomfort with the use of this line of argument to support prohibition commonly is resolved by presumptions that users sooner or later will become addicted and that users without problems do not really exist.

A common form of prohibition of use in village and tribal societies has been sumptuary rules restricting use to particular status groups, most commonly the most powerful segments of the society. Depending on the culture, a variety of arguments are offered for the inability of lower-status groups to handle drug use appropriately. Because psychoactive drugs offer visions of an alternative reality (Stauffer) and may be associated with disinhibition, dominant groups may fear challenges to their power if subordinates have access to drugs (Morgan). The universalist ethic of modern states has made explicit sumptuary restrictions untenable, with the substantial exception of prohibitions on use by children. Even the provisions, still common in U.S. state laws, that the names of habitual drunkards be posted and that those listed be refused service of alcoholic drinks are largely unenforced because of their perceived interference with individual liberties.

A third form of modified prohibition of use that often is employed in modern societies is limitation to medicinal use. The individual's supply of such medications is controlledPage 140 | Top of Article by state-licensed professionals who are backed up by a state system of market controls. National controls on psychopharmaceuticals are backed up by an unusual and elaborate international control structure (Bruun et al.; Room and Paglia). In principle, prescription and use of these drugs are limited to therapeutic purposes. For psychoactive drugs, which commonly are prescribed to relieve negative affective states or mental distress, the definition of therapeutic use often is quite wide, and a substantial proportion of the resources of the health system in industrial societies is absorbed in superintending the provision of psychoactive drugs.

Except for methadone as a remedy for heroin addiction and nicotine as a remedy for tobacco smoking, it generally is considered illegitimate to prescribe a drug to help a person maintain a habitual pattern of use without withdrawal or other distress. Use for pleasure or for the sake of the psychoactive experience is considered nontherapeutic, and so the functions of drugs that are considered psychopharmaceuticals always are described in terms of the relief of distress rather than the provision of pleasure. To some extent the medical prescription system in a modern state serves as a covert form of control by status differentiation, according to the prejudices of the prescriber; for instance, older and more respectable adults find it easier than do the younger and more disreputable to obtain a prescription for a psychopharmaceutical.

INFLUENCING THE PATTERN OF USE. An enormous variety of formal and informal strategies have been used to influence the amount, pattern, and context of the use of drugs. Among the potential aims of those strategies is the public health goal of reducing the prevalence of hazardous use.

Controlling availability. One class of such strategies attempts to reduce drug-related problems by controlling the market in drugs by means of taxes, general restrictions on availability, or user-specific restrictions (Room, 2000; Babor et al.). Public health considerations are one reason among several that governments tax legally available drugs such as alcohol and tobacco. Those taxes often constitute a substantial portion of the price to the consumer. Raising taxes does diminish levels of use among heavier as well as lighter users, although demand usually diminishes proportionately less than the increase in price; that is, demand is relatively inelastic. Thus, short of levels that create an opening for a substantial illicit market, raising taxes on drugs tends both to have positive public health effects and to increase government revenues.

Governments often also control the conditions of availability, particularly for alcohol. Through a system of retail licenses or a government monopoly of sales, limits are placed on the hours and conditions of sale. Changes in those limits sometimes have been found to affect patterns of consumption and of alcohol-related problems (Babor et al.). However, with the strengthening of the ideology of consumer sovereignty—legal goods should be readily available, with purchases limited only by the consumer's means—controls on availability tend to have been loosened in the contemporary period (Mäkelä et al.).

A generally stronger and more direct effect on hazardous alcohol consumption has been found to result from measures that ration or restrict the availability of alcohol for specific purchasers (Babor et al.). A general ration limit for all purchasers restricts heavy consumption or at least raises the effective price, but such measures strongly conflict with the ideology of consumer sovereignty and are thus politically impracticable nearly everywhere. As was noted above, proscriptions or limits on sales to named heavy users also have fallen out of favor because they are considered infringements on individual liberty.

Controlling the circumstances of use. Another class of strategies aims to deter drinking or drug use in particularly hazardous circumstances, usually through the use of criminal sanctions. The prototypical situation is driving after drinking. Because alcohol consumption impairs the ability to drive a vehicle, most countries treat driving with a blood-alcohol level above a set limit as a criminal offense, and enforcement of those laws often absorbs a substantial proportion of the criminal justice system's resources. Popular movements as well as policy makers have expended much energy, particularly in the United States and other Anglophone and Scandinavian countries, in seeking a redefinition of drunk driving as a serious crime rather than a "folk crime" (Gusfield). This type of situational limit or prohibition has been extended to other skill-related tasks and also has been applied to driving after using other psychoactive drugs, particularly illicit drugs. A related development has sought to eliminate illicit drug use in working populations and alcohol use in the workplace by means of random urine testing of workers, with job loss as the sanction (Zimmer and Jacobs).

The ethics of this measure, which was pushed strongly by the U.S. government in the 1980s, are controversial, particularly because the tests detect illicit drug use that has not necessarily affected work performance (Macdonald and Roman). Random blood-alcohol tests of drivers to deter drinking before driving also have proved controversial: They are effective, well accepted, and widely applied in Australia (Homel et al.; Peek-Asa); legally permissible but not intensively applied in the United States; and viewed as anPage 141 | Top of Article impermissible infringement on individual liberty and privacy in many countries.

Education and persuasion about use. A third class of strategies seeks to educate people or persuade them not to engage in hazardous drug use. Because such strategies are seen as the least coercive, at least for those beyond school age, they are used very widely and commonly despite the frequent lack of clear evidence on their effectiveness (Paglia and Room). Education of schoolchildren about the hazards of drug use is very widespread, indeed nearly ubiquitous, in the United States. Most countries also have made at least a token effort at public information campaigns about the hazards of tobacco smoking, and poster and slogan campaigns against drinking before driving and illicit drug use are also widespread. Other public information campaigns on alcohol have promoted limits on drinking (e.g., suggestions of safe levels in Britain and Australia) or campaigned against drinking in various hazardous circumstances.

Often these public information campaigns compete for attention in a media environment saturated with advertising on behalf of use from tobacco or alcohol companies. In the last two decades of the twentieth century some governments imposed substantial restrictions on tobacco and, to a lesser extent, alcohol advertising, for example, banning advertisements on electronic media, and mandated warning labels in advertisements or on product packages. These restrictions often have precipitated court fights about the constitutional permissibility of restrictions on the freedom of "commercial speech."

REDUCING THE HARM FROM USE. The strategies considered above are directed primarily at influencing the fact or pattern of use. They thus fall into the category of either supply reduction or demand reduction, to use terminology commonly applied to the use of illicit drugs. Since the late 1980s substantial attention has been directed toward a third option: harm reduction, or strategies that reduce the problems associated with drug use without necessarily reducing drug use (O'Hare et al.; Heather et al.). Attention to this class of strategies has a somewhat longer history for alcohol (Room, 1975). Usually these strategies focus on the physical or social environment of drug use, seeking physical, temporal, or cultural insulation of the drug use from harm. Thus, needle exchanges are intended to remove the risk of HIV infection from injection drug use, and seat belts and air bags insulate drivers who drink and those around them from the possibility of becoming casualties.

The debate over harm reduction strategies for illicit drugs has raised classic ethical issues for public health. Some argue that insulating the behavior from harm will encourage and thus increase the prevalence of the undesirable behavior. A further consideration is the effectiveness of the insulation provided. Thus, efforts to provide a safer tobacco cigarette largely have been undercut by compensatory changes in puffing and inhaling by smokers. At an empirical level it seems that insulating drug use from harm does not necessarily increase the prevalence of drug use (Yoast et al.). Even if it did, an old public health tradition that is epitomized by the operation of venereal disease clinics would argue that reducing the immediate risk of harm has a higher ethical priority than affecting the prevalence of disapproved behaviors.

The Political Reality in the Early 2000s: Lopsided Policies

The United States and many other countries have experienced recurring "moral panics" in recent decades concerning illicit drug use and have invested substantial resources in efforts to prevent such use. These resources have been invested largely in two areas: a particular preventive strategy—interdicting the illicit market—and the provision of treatment. The first strategy has received the greatest investment of government resources. There was a substantial decrease in illicit drug use in North America in the late 1980s and early 1990s, but it was followed by a rise in the 1990s.

Governments often are blamed for these ebbs and flows, but they may have more to do with cyclical patterns in youth fashions and social mores. The illicit market remains strong, and drug-related imprisonments have helped propel the United States to having the highest rate of incarceration among industrial societies. Meanwhile, the highest rates of health and social harm come from legal drugs. For instance, the World Health Organization (WHO) estimates that 13.3 percent of the net disability and death (in disability-adjusted life-years) in the subregion consisting of the United States, Canada, and Cuba is attributable to tobacco, 7.8 percent to alcohol, and 2.6 percent to illicit drugs (Ezzati et al.), yet alcohol and tobacco have received a much lower priority. In government policy making on these licit substances public health considerations often have been subordinated to economic concerns. In recent years, for example, the United States has successfully attacked control structures and forced a greater availability of both alcohol and tobacco in other countries through lawsuits under the General Agreement on Tariffs and Trade (Ferris et al.).

A substantial emphasis on the treatment of addiction has accompanied the attention paid to prevention. However, in this mixed policy environment the role of treatment has been highly differentiated by the type of drug. To a large extent tobacco smoking has continued to be defined as a health problem rather than a social problem, with thePage 142 | Top of Article emphasis on the health consequences of smoking rather than the physical dependence of smokers on tobacco. Thus, there has been very little public provision of treatment for smoking addiction; most of those who have quit have done it by themselves or by using nicotine substitutes.

At the other extreme the goals for an illicit drug treatment system have been highly ambitious: In theory, in the mid-1970s and again in the late 1980s, the United States aspired to provide treatment to every unincarcerated addict. Quite explicitly, treatment for illicit drug use has been seen as a form of social control, and a high degree of coercion has been taken for granted (Gerstein and Harwood). On occasion U.S. drug strategies have argued for the provision of treatment as a means to encourage courts to be tougher on those who choose not to accept it (Strategy Council on Drug Abuse), and drug treatment agencies have argued routinely for maintaining jail sentences for drug use in order to force users into treatment as an alternative.

In the case of alcohol there also has been substantial growth in treatment provision, and not only in the United States (Klingemann et al.). However, in the United States alcohol treatment until recently was only an adjunct of the criminal justice system, and it remains quite separate in many countries. The growth of alcohol treatment provision, it has been argued, accompanied and served as a "cultural alibi" for the dismantling of the alcohol control structure left behind by the temperance era (Mäkelä et al.). Although there is an increasing contradiction between the demands for sobriety in a technological environment and the increased market availability of alcohol, managing that contradiction is seen as a character test for the individual consumer, with treatment for alcoholism provided for those deemed to have failed the test.

These policy trends for alcohol and tobacco apply in broad terms to other industrial countries, although high-tax strategies have been applied more commonly outside the United States, particularly for tobacco. For illicit drugs the U.S. "drug war" ideology has been exerted internationally as well as at home (Traver and Gaylord). Through mechanisms such as the international narcotics control conventions and through active multilateral and bilateral diplomacy the United States has been relatively successful in maintaining and often strengthening legal prohibitions. Nevertheless, the international illicit market continues to grow. In debates about drug policies in the 1990s and early 2000s the practical relevance and the ethics of U.S. policies have been questioned increasingly by scholars (Bertram et al.; MacCoun and Reuter).

ROBIN ROOM (1995)

REVISED BY AUTHOR

SEE ALSO: Addiction and Dependence; Alcoholism; Public Health; Smoking

BIBLIOGRAPHY

Austin, Gregory. 1979. "Perspectives on the History of Psychoactive Substance Use." In Research Issues, vol. 24. National Institute on Drug Abuse, DHEW Publication No. (ADM) 79–810. Washington, D.C.: U.S. Government Printing Office.

Babor, Thomas; Caetano, Raul; Casswell, Sally; et al. 2003. Alcohol—No Ordinary Commodity: Research and Public Policy. Oxford: Oxford University Press.

Bertram, Eva; Blachman, Morris; Sharpe, Kenneth; and Andreas, Peter. 1996. Drug War Politics: The Price of Denial. Berkeley: University of California Press.

Bruun, Kettil. 1970. "Finland: The Non-Medical Approach." In Proceedings of the 29th International Congress on Alcoholism and Drug Dependence, ed. L.G. Kiloh and David S. Bell. Australia: Butterworths.

Bruun, Kettil; Pan, Lynn; and Rexed, Ingemar. 1975. The Gentlemen's Club: International Control of Drugs and Alcohol. Chicago and London: University of Chicago Press.

Christie, Nils, and Bruun, Kettil. 1968. "Alcohol Problems: The Conceptual Framework." In Proceedings of the 28th International Congress on Alcohol and Alcoholism, vol. 2, ed. Mark Keller and Timothy G. Coffey. Highland Park, NJ: Hillhouse Press.

Dillon, Patrick. 2003. Gin: The Much-Lamented Death of Madam Geneva: The Eighteenth-Century Gin Craze.Boston: Justin, Charles & Co.

Elster, Jon, and Skog, Ole-Jørgen, eds. 1999. Getting Hooked: Rationality and Addiction. Cambridge, Eng.: Cambridge University Press.

Ezzati, Majid; Lopez, Alan D.; Rodgers, Anthony; Vander Hoorn, Stephen; Murray, Christopher J. L.; and the Comparative Risk Assessment Collaborating Group. 2002. "Selected Major Risk Factors and Global and Regional Burden of Disease." Lancet 360: 1347–1360.

Ferris, Jacqueline; Room, Robin; and Giesbrecht, Norman. 1993. "Public Health Interests in Trade Agreements on Alcoholic Beverages in North America." Alcohol Health and Research World 17: 235–241.

Fingarette, Herbert. 1988. Heavy Drinking: The Myth of Alcoholism as a Disease. Berkeley and Los Angeles: University of California Press.

Gerstein, Dean R., and Harwood, Henrick J., eds. 1990. Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems, vol. 1. Committee for the Substance Abuse Coverage Study, Institute of Medicine. Washington, D.C.: National Academy Press.

Gusfield, Joseph R. 1981. The Culture of Public Problems: Drinking-Driving and the Symbolic Order. Chicago: University of Chicago Press.

Page 143 | Top of Article

Heather, Nick; Wodak, Alex; Nadelmann, Ethan; and O'Hare, Pat, eds. 1993. Psychoactive Drugs and Harm Reduction: From Faith to Science. London: Whurr Publishers.

Hilts, Philip J. 1994. "Embattled Tobacco: One Maker's Struggle." New York Times, June 16, 17, 18.

Homel, Ross; Carseldine, Don; and Kearns, Ian. 1988. "Drink- Driving Countermeasures in Australia." Alcohol, Drugs and Driving 4: 113–144.

Husak, Douglas N. 1992. Drugs and Rights. Cambridge, Eng.; New York; and Oakleigh, Victoria, Australia: Cambridge University Press.

Jellinek, Elwyn M. 1952. "Phases of Alcohol Addiction." Quarterly Journal of Studies on Alcohol 13: 673–684.

Jellinek, Elwyn M. 1960. The Disease Concept of Alcoholism. New Haven, CT: Hillhouse Press.

Keane, Helen. 2002. What's Wrong with Addiction? Melbourne: Melbourne University Press.

Klingemann, Harald; Takala, Jukka-Pekka; and Hunt, Geoffrey, eds. 1992. Cure, Care or Control: Alcoholism Treatment in Fourteen Countries. Albany: State University of New York Press.

Levine, Harry Gene. 1978. "The Discovery of Addiction: Changing Concepts of Habitual Drunkenness in American History." Journal of Studies on Alcohol 39: 143–174.

MacCoun, Robert, and Reuter, Peter. 2001. Drug War Heresies: Learning from Other Vices, Times and Places.Cambridge, Eng.: Cambridge University Press.

Macdonald, Scott, and Roman, Paul M., eds. 1994. Drug Testing in the Workplace: Research Findings and Perspectives, vol. 11 of Research Advances in Alcohol and Drug Problems. New York and London: Plenum.

Mäkelä, Klaus; Room, Robin; Single, Eric; et al. 1981. Alcohol, Society, and the State: 1. A Comparative Study of Alcohol Control. Toronto: Addiction Research Foundation.

Moore, Mark, and Gerstein, Dean, eds. 1981. Alcohol and Public Policy: Beyond the Shadow of Prohibition.Washington, D.C.: National Academy Press.

Morgan, Patricia. 1983. "Alcohol, Disinhibition, and Domination: A Conceptual Analysis." In Alcohol and Disinhibition: Nature and Meaning of the Link, ed. Robin Room and Gary Collins. NIAAA Research Monograph No. 12, DHHS Publication No. (ADM) 83–1246. Washington, D.C.: U.S. Government Printing Office.

O'Hare, Pat A.; Newcombe, Russell; Matthews, Alan; Buning, Ernst C.; and Drucker, Ernest. 1992. The Reduction of Drug-Related Harm. London and New York: Routledge.

Paglia, Angela, and Room, Robin. 1999. "Preventing Substance Use Problems among Youth: A Literature Review and Recommendations." Journal of Primary Prevention 20: 3–50.

Partanen, Juha. 1991. Sociability and Intoxication: Alcohol and Drinking in Kenya, Africa, and the Modern World, vol. 39. Helsinki: Finnish Foundation for Alcohol Studies.

Peek-Asa, Corinne. 1999. "Effect of Random Alcohol Screening in Reducing Motor Vehicle Crash Injuries."American Journal of Preventive Medicine suppl. 16(1): 57–67.

Pernanen, Kai. 1976. "Alcohol and Crimes of Violence." In The Biology of Alcoholism, vol. 4: Social Aspects of Alcoholism, ed. Benjamin Kissin and Henri Begleiter. New York and London: Plenum.

Rehm, Jürgen; Sempos, Christopher T.; and Trevisan, Maurizio. 2003. "Average Volume of Alcohol Consumption, Patterns of Drinking and Risk of Coronary Heart Disease—A Review." Journal of Cardiovascular Risk 10: 15–20.

Robicsek, Francis. 1978. The Smoking Gods: Tobacco in Maya Art, History and Religion. Norman: University of Oklahoma Press.

Room, Robin. 1975. "Minimizing Alcohol Problems." In Proceedings of the Fourth Annual Alcoholism Conference of the National Institute on Alcohol Abuse and Alcoholism: Research, Treatment and Prevention, ed. Morris Chafetz. DHEW Publication No. ADM 76–284. Washington, D.C.: U.S. Government Printing Office.

Room, Robin. 1985. "Alcohol as a Cause: Empirical Links and Social Definitions." In Currents in Alcohol Research and the Prevention of Alcohol Problems, ed. Jean-Pierre von Wartburg, Pierre Magnenat, Richard Müller, and Sonja Wyss. Berne, Stuttgart, and Toronto: Hans Huber.

Room, Robin. 2000. "Control Systems for Psychoactive Substances." In Nicotine and Public Health, ed. Roberta Ferrence, John Slade, Robin Room, and Marilyn Pope. Washington, D.C.: American Public Health Association.

Room, Robin. 2001a. "Governing Images in Public Discourse about Problematic Drinking." In International Handbook of Alcohol Dependence and Problems, ed. Nick Heather, Timothy J. Peters, and Tim Stockwell. Chichester, Eng.: John Wiley.

Room, Robin. 2001b. "Intoxication and Bad Behaviour: Understanding Cultural Differences in the Link." Social Science and Medicine 53: 189–198.

Room, Robin. 2001c. "New Findings in Alcohol Epidemiology." In Alcohol in the European Region: Consumption, Harm and Policies, by Nina Rehn with Robin Room and Griffith Edwards. Copenhagen: World Health Organization Regional Office for Europe.

Room, Robin, and Paglia, Angela. 1999. "The International Drug Control System in the Post–Cold War Era: Managing Markets or Fighting a War?" Drug and Alcohol Review 18: 305–315.

Stauffer, Robert. 1971. The Role of Drugs in Political Change. New York: General Learning Press.

Strategy Council on Drug Abuse. 1973. Federal Strategy for Drug Abuse and Drug Traffic Prevention. Washington, D.C.: U.S. Government Printing Office.

Szasz, Thomas. 1985. Ceremonial Chemistry, rev. edition. Holmes Beach, FL: Learning Publications.

Traver, Harold H., and Gaylord, Mark S., eds. 1992. Drugs, Law and the State. New Brunswick, NJ, and London: Transaction Publishers.

Valverde, Mariana. 1998. Diseases of the Will: Alcohol and the Dilemmas of Freedom. Cambridge, Eng., and New York: Cambridge University Press.

Page 144 | Top of Article

Warner, Jessica. 2002. Craze: Gin and Debauchery in an Age of Reason. New York: Four Walls Eight Windows.

Wasson, R. Gordon. 1984. "Distilled Alcohol Dissemination." Drinking and Drug Practices Surveyor 19: 6.

Yoast, Richard; Williams, Michael A.; Deitchman, Scott D.; and Champion, Hunter C. 2001. "Report of the Council on Scientific Affairs: Methadone Maintenance and Needle-Exchange Programs to Reduce the Medical and Public Health Consequences of Drug Abuse." Journal of Addictive Diseases 20: 15–40.

Zimmer, Lynn, and Jacobs, James B. 1992. "The Business of Drug Testing: Technological Innovation and Social Control." Contemporary Drug Problems 19: 1–26.

Zinberg, Norman E. 1984. Drug, Set and Setting: The Basis for Controlled Intoxicant Use. New Haven, CT: Yale University Press.

Source Citation: ROOM, ROBIN. "Alcohol and other Drugs in a Public Health Context." Encyclopedia of Bioethics. Ed. Stephen Post. Vol. 1. 3rd ed. New York: Macmillan Reference USA, 2004. 137-144. 5 vols. Gale Virtual Reference Library. Thomson Gale. National Institutes of Health. 19 Dec. 2007 
<http://ezproxyhhs.nihlibrary.nih.gov:2741/gvrl/infomark.do?&contentSet=EBKS&type=retrieve&tabID=T001&prodId=GVRL&docId=CX3402500042&eisbn=0-02-865916-3&source=gale&userGroupName=nihncrr&version=1.0>.
How to Cite

Thomson Gale Document Number: CX3402500042


View other articles linked to these index terms:

Page locators that refer to this article are not hyper-linked.

Addiction and dependence, treatment, 1: 141-142, 4: 2008 , 4: 2009-2010 Alcohol use, 1: 137-144, 2: 1155Availability control of drugs, 1: 140 Cultural issues drug use policy, 1: 139 psychoactive drug use, 1: 138 Diagnosisprofessional-patient relationship, 1: 2 , 1: 138, 4: 2133 , 4: 2135 , 4: 2137 Drug policy, 1: 139-142 Drug testingemployment, 1: 62 , 1: 140-141 Drunk driving, 1: 140, 1: 145 Harm reduction drug policy, 1: 141, 2: 1042 Historyalcohol use, 1: 144 prohibition of drugs and alcohol, 1: 139-140 Islam drug use prohibition, 1: 139 Medicinal use of psychoactive drugs, 1: 139-140 Prohibition of drugs and alcohol, 1: 139-140, 2: 1038-1041 , 4: 2232-2233Psychoactive drug use, 1: 137-144 Public health, alcohol and other drug use, 1: 137-144, 4: 2211 , 4: 2232-2233Public information campaigns, 1: 141 Smoking, cessation, 1: 141-142 Substance abuse, drug use education, 1: 141Taxes on legal drugs, 1: 140 Treatment addiction and dependence, 1: 65-66 , 1: 141-142 substance abuse, 1: 141-142 United Kingdom drug policy, 1: 139 United States substance abuse treatment policies, 1: 141-142


Suicides Rising in Middle Age

A cohort effect from the 60's?


http://news.yahoo.com/s/ap/20071214/ap_on_he_me/suicide_middle_aged;_ylt
=Ao470WXVOyJwCVfObVKvrDO9j7AB


CDC: Suicides among middle-aged spikes By MIKE STOBBE, AP Medical Writer

Thu Dec 13, 10:55 PM ET


ATLANTA - The suicide rate among middle-aged Americans has reached its
highest point in at least 25 years, a new government report said
Thursday.

The rate rose by about 20 percent between 1999 and 2004 for U.S.
residents ages 45 through 54 - far outpacing increases among younger
adults, the U.S. Centers for Disease Control and Prevention reported.

In 2004, there were 16.6 completed suicides per 100,000 people in that
age group. That's the highest it's been since the CDC started tracking
such rates, around 1980. The previous high was 16.5, in 1982.

Experts said they don't know why the suicide rates are rising so
dramatically in that age group, but believe it is an unrecognized
tragedy.

The general public and government prevention programs tend to focus on
suicide among teenagers, and many suicide researchers concentrate on the
elderly, said Mark Kaplan, a suicide researcher at Portland State
University.

"The middle-aged are often overlooked. These statistics should serve as
a wake-up call," Kaplan said.

Roughly 32,000 suicides occur each year - a figure that's been holding
relatively steady, according to the Suicide Prevention Action Network,
an advocacy group.

Experts believe suicides are under-reported. But reported rates tend to
be highest among those who are in their 40s and 50s and among those 85
and older, according to CDC data.

The female suicide rates are highest in middle age. The rate for males -
who account for the majority of suicides - peak after retirement, said
Dr. Alex Crosby, a CDC epidemiologist.

Researchers looked at death certificate information for 1999 through
2004. Overall, they found a 5.5 percent increase during that time in
deaths from homicides, suicides, traffic collisions and other injury
incidents.

The largest increases occurred in the 45 to 54 age group. A large
portion of the jump in deaths in that group was attributed to
unintentional drug overdoses and poisonings - a problem the CDC reported
previously.

But suicides were another major factor, accounting for a quarter of the
injury deaths in that age group. The suicide count jumped from 5,081 to
6,906 in that time.

In contrast, the suicide rate for people in their 20s - the other age
group with the most dramatic increase in injury deaths - rose only 1
percent.

uicide Risk High for Middle-Aged Whites

White Women See Biggest Spike in Suicide Rates; African-Americans See Significant Decline, Study Shows
By Kelley Colihan
WebMD Health News
Reviewed by Louise Chang, MD

Oct. 21, 2008 -- It's a troubling trend that researchers say we know little about.

A new study shows that middle-aged white people are at high risk for suicide, as the U.S. suicide rate spiked among that group during 1999-2005.

Researchers found that white women made up the largest increase in suicides, although white men still make up the largest number of people who kill themselves.

Suicide rates were down among African-Americans and remained stable for Asian and Native Americans among that same time period.

The study and report by Guoqing Hu, PhD, from Central South University in Changsha, China, and colleagues included co-author Susan Baker, MPH, from the Johns Hopkins Bloomberg School of Public Health.

Why the increase? In a news release, Baker says researchers are not sure: "While it would be straightforward to attribute the results to a rise in so-called mid-life crises, recent studies find that middle age is mostly a time of relative security and emotional well-being."

She urges further research to "explore societal changes that may be disproportionately affecting the middle-aged in this country."

Researchers crunched numbers from data based on files from the National Center for Health Statistics on suicide trends from 1999 to 2005.

Suicide Rates

Here are the main results:

  • The suicide rate for white women 40-64 years old went up 3.9% per year during the study period.
  • The suicide rate among white men in the same age group increased 2.7% per year.
  • Overall suicide rates went up for whites -- 1.1% per year. Suicide rates went down significantly for African-Americans -- 1.1% per year.
  • Suicide rates remained stable for Asian and Native Americans.

The authors write that suicide is the fourth-leading cause of death among people aged 10 to 64.

In a news release, Baker says the results signal a change that could lead to better prevention. "Historically, suicide prevention programs have focused on groups considered to be at highest risk, teens and young adults of both genders as well as elderly white men. This research tells us we need to refocus our resources to develop prevention programs for men and women in their middle years."

In background information presented with the findings, researchers map out suicide risk factors such as:

  • A previous suicide attempt
  • Mental or physical illness or a family history of mental illness
  • A history of sexual assault or abuse
  • Family history of suicide
  • A sense of hopelessness
  • Stress
  • Having a gun in the home or access to other methods to suicide
  • Seeing images of suicide in the media

The authors also offer some of the ways to protect against suicide:

  • Learning or developing new coping or problem-solving skills
  • Adhering to cultural or religious beliefs that discourage suicide
  • Strong support from family and/or community members
  • Available high-quality treatment for mental or physical disorders or addictions

The results are published online in the American Journal of Preventive Medicine and will appear in the journal's December 2008 print version.

Drugs of Abuse and the Aging Brain

Drugs of Abuse and the Aging Brain
Neuropsychopharmacology (2008) 33, 209-218
Gayathri J Dowling, Susan R B Weiss and Timothy P Condon National
Institute on Drug Abuse, NIH, DHHS, Bethesda, MD, USA

ABSTRACT

Substance abuse among older adults has received little attention in the
past, presumably because this population has traditionally accounted for
only a small percentage of the drug abuse problem in the United States.

The aging of the baby boomer generation (born 1946-1964), however, will
soon swell the ranks of older adults and dramatically alter the
demography of American society.

Several observations suggest that this expansion will likely be
accompanied by a precipitous increase in the abuse of drugs, including
prescription medications and illicit substances, among older adults.

While it is now evident that the brain changes continuously across life,
how drugs of abuse interact with these age-related changes remains
unclear.

The dynamic nature of brain function, however, suggests that substance
abuse during older age may augment the risks and require unique
considerations for diagnosis and treatment.

In addition to describing current and projected prevalence estimates of
substance abuse among older adults, the present review discusses how
aging affects brain systems involved in drug abuse, and explores the
potential impact of drug abuse on the aging brain.

Future directions for substance abuse research among older adults will
also be considered.

Reducing Wait Time Improves Treatment Access, Retention

SAMHSA News - September/October 2007, Volume 15, Number 5


Reducing Wait Time Improves Treatment Access, Retention (Part 1)

Seeking help for a substance abuse problem can be one of the most difficult decisions people ever make. Whether they’re motivated by a frustrated spouse, a legal problem, or simply a desire to change their lives, their resolve can often be shaky. Just about anything can become an excuse to break an appointment or even drop out of treatment altogether.

Now SAMHSA’s Center for Substance Abuse Treatment (CSAT) is helping states and treatment providers get rid of overwhelming intake forms, long waits for appointments, and other barriers to efficient services.

Launched in 2006, the 3-year Strengthening Treatment Access and Retention–State Implementation (STAR-SI) program promotes the use of an approach pioneered in the business world—“continuous quality improvement”—to get people into outpatient treatment and keep them there until they’re better.

The grantees include state agencies in Florida, Illinois, Iowa, Maine, Ohio, South Carolina, and Wisconsin. In addition, three other state agencies have joined STAR-SI. Montana is funded through the Single State Agency, and Oklahoma and New York are funded by the Robert Wood Johnson Foundation. “The STAR-SI initiative is based on the idea that small changes can bring big rewards,” said SAMHSA Administrator Terry L. Cline, Ph.D. “You identify a problem, test a solution, and move on to the next problem. It’s an incremental approach that can have a huge impact.”

Back to Top

A “Rapid-Cycle” Process

The STAR-SI program builds on findings from the Network for the Improvement of Addiction Treatment (NIATx), a joint initiative of CSAT and the Robert Wood Johnson Foundation (see What Is NIATx?).

That original NIATx initiative began in 2003 to help grantees set an agenda for improving addiction services and adopting evidence-based treatment practices. A 3-year pilot project, it included CSAT’s Strengthening Treatment Access and Retention (STAR) program, launched in 13 states, and the Robert Wood Johnson counterparts. (See SAMHSA News online, fall 2003.)

In that effort, grantees successfully increased client access and retention by making simple changes. These changes included everything from streamlining intake procedures and eliminating unnecessary paperwork to extending clinic hours and using incentives and “motivational interviewing” to engage clients during the early phases of treatment.

“When treatment providers make these small changes in the ‘process’ of delivering care, they can substantially improve outcomes,” said CSAT Director H. Westley Clark, M.D., J.D., M.P.H. “Treatment providers are powerful agents of improvement and organizational change.”

STAR-SI grantees now use the same model developed by their predecessors.

“We demonstrated the use of this quality improvement technology in treatment settings. But we wanted to move from the treatment level to the state level,” said Frances Cotter, M.P.H., Quality Improvement Team Lead in CSAT’s Division of Services Improvement.

Called process improvement, the incremental approach championed by NIATx consists of identifying a problem, setting a goal for improvement, pilot-testing possible solutions, and analyzing the outcome.

Once one change has proven successful, the organization—whether it’s an entire state agency or an individual treatment facility—quickly moves on to the next area that needs improvement.

The changes typically cost little or nothing and are put into effect just 3 or 4 weeks after a problem has been identified.

“We encourage people to make small, simple changes quickly,” said NIATx Deputy Director Todd Molfenter, Ph.D. “Even if you’re trying to lose weight or making other changes in your personal life, you rarely get things right the first time. You have to try different things and see how they work. That’s what this process encourages.”

Back to Top

Back to Graphic Version


Reducing Wait Time Improves Treatment Access, Retention (Part 2)

Walk-Throughs

To identify problems, the agencies involved in STAR-SI start the process with a walk-through. (See STAR-SI in Action: South Carolina.) Putting themselves in the shoes of clients and family members, staff experience the process of intake and engagement from the other side of the table.

What they discover can be startling. It may take way too long to get an initial appointment. There may be an overwhelming number of forms to fill out. The lobby may be unwelcoming and unappealing. Any of these factors may derail potential clients on their track toward their first treatment session.

Simple changes can help ensure that doesn’t happen. Based on findings from the walk-through, a “change team” identifies a problem, brainstorms a solution, puts it into effect on a small scale, evaluates its impact, and tweaks things if necessary. The solution may entail allowing walk-ins, calling clients the day before their appointments, relocating intake interviews to a more private space, or simply giving the lobby walls a fresh coat of paint.

Dramatic Results

One key characteristic of the NIATx model is its basis in data. Instead of making changes based on gut feelings, participants collect baseline data and then rigorously evaluate the impact of proposed changes.

During the original NIATx initiative, CSAT’s STAR grantees and their Robert Wood Johnson counterparts proved that the model substantially increased clients’ access and retention.

At the end of the original grants cycle, the 39 founding members (including the STAR program) reported the following results:

  • Waiting time between clients’ first request for help and their first treatment session dropped by nearly 35 percent.

  • The number of no-shows for appointments dropped by 33 percent.

  • Grantees reported a 21-percent increase in admissions to treatment.

  • Grantees saw an increase of more than 22 percent in treatment continuation.

The STAR-SI grantees hope to achieve similar results. They are tracking the number of treatment providers participating in STAR-SI, the number of clients admitted to treatment, the length of time clients stay in treatment, and the number of treatment sessions provided between intake and discharge. In addition, the grantees will collect data on at least two state-specific measures.

Back to Top

Collaborative Learning

One strategy for achieving STAR-SI’s goals is peer-to-peer learning. Grantees and participating treatment agencies share success stories, ask for advice, and offer feedback to other STAR-SI participants both within their states and across the Nation. Grantees also benefit from coaching from NIATx consultants and peer mentors.

When states or agencies find a change to be successful, they put it into effect across their entire organization. States are gradually increasing the number of agencies engaged in the effort. And CSAT is exploring the idea of expanding the effort to other phases of outpatient treatment.

“STAR-SI is currently applying process improvement methods to improving access and engagement, which is usually defined as the first 30 days of treatment,” said Ms. Cotter. “Our future plans are to examine the effect of these methods at the next phase of treatment, which involves hand-offs from one level of care to another or from the criminal justice system to community-based treatment.”

For more information about SAMHSA’s Strengthening Treatment Access and Retention grant program and other substance abuse prevention and treatment programs, visit SAMHSA’s Web site atwww.samhsa.gov.

Back to Top

Back to Graphic Version

Data on Health and Well-being of American Indians, Alaska Natives, and Other Native Americans

    For your information, two data-related reports pertaining to American Indians, Alaska Natives and Native Americans  produced under contract for ASPE’s Office of Human Services Policy are now available on the ASPE website:

    Data on Health and Well-being of American Indians, Alaska Natives, and Other Native Americans.  Data Catalog  This data catalog is a compilation of existing data sources pertaining to American Indian/Alaska Native/Native American (AI/AN/NA) populations. The Catalog includes sources of socioeconomic and health data using national and some state-level surveys.  Information on 68 data sources including their characteristics and limitations is included in the catalog.  This data catalog is a valuable reference for researchers, analysts and policymakers interested in AI/AN/NA issues.  It can be found at: http://aspe.hhs.gov/hsp/06/Catalog-AI-AN-NA  

    Gaps and Strategies for Improving AI/AN/NA Data - Final Report  This report identifies gaps in AI/AN/NA data on health and well-being, strategies for improving AI/AN/NA data availability and quality, and some current initiatives underway within HHS and other federal agencies that are intended to improve these data.  It is located at: http://aspe.hhs.gov/hsp/07/AI-AN-NA-data-gaps

You can waste many a work hour on this fascinating site of Oddities

See also:

http://www.museumofhoaxes.com/hoax/top/experiments/

Kircher Society

You can waste many a work hour on this fascinating site of natural and
constructed oddities:

http://www.kirchersociety.org/

Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments


    

Psychedelic Medicine: New Evidence for

Hallucinogenic Substances as Treatments [2 volumes]

                               Edited by Michael J. Winkelman, Ph.D. and Thomas B. Roberts, Ph.D 

Roberts's faculty webpage:

Winkelmans' website: http://www.public.asu.edu/~atmxw/

Psychedelic substances present in nature have been used by humans across hundreds of years to produce mind-altering changes in thought, mood, and perception - changes we do not experience otherwise except rarely in dreams, religious exaltation, or psychosis. U.S. scientists were studying the practical and therapeutic uses for hallucinogens, including LSD and mescaline, in the 1950s and 1960s supplied by large manufacturers including Sandoz. But the government took steps to ban all human consumption of hallucinogens, and thus the research. By 1970s, all human testing was stopped. Medical concerns were not the issue, the ban was moved by social concerns, not the least of which were created by legendary researcher Timothy Leary, a psychologist who advocated free use of hallucinogens by all who desired. Nationwide, however, a cadre of scholars and researchers has persisted in pushing the federal government to again allow human testing. And the moratorium has been lifted. The FDA has begun approving hallucinogenic research using human subjects. In these groundbreaking volumes, top researchers explain the testing and research underway to use - under the guidance of a trained provider - psychedelic substances for better physical and mental health.

 

“These books are a comprehensive and scholarly review of the current status of the therapeutic potential of hallucinogens. The contributors represent an outstanding group of scientists, scholars and clinicians, most of whom have had direct experience using and administering these drugs in either therapeutic or religious contexts. The result is an impressive collection. The authors provide scholarly historical reviews of the use of these drugs, as well as detailed instructions and advice for the clinician on how to administer these drugs safely and effectively in a therapeutic context. The authors provide a balanced view and acknowledge the many risks and pitfalls of improper use of these drugs. Likely to be of interest to scientists, clergy, mental health professionals, and anyone interested in the mind. It provides an up to date review of the status of h allucinogens in modern medicine, as well as a historical review of their status in the past. It is highly recommended.” --Harriet de Wit, PhD Professor, Department of Psychiatry The University of Chicago

 

 

 “Until they were caught up in the cultural revolution of the 1960s, hallucinogens were being seriously examined by top researchers for their potential to alleviate many human ills. The contributors to this volume make a persuasive case that science should now do more to pursue these questions.” --Professor Jonathan D. Moreno, University of Pennsylvania Center for Bioethics

 

“Roberts and Winkelman have assembled one of the most impressive and comprehensive collection of writings in the field of psychedelic medicine. The chapters, written by first-rate academic scholars, are rigorous and clear. The topics range from neuroscience to the legal, spiritual, medicinal, and ethical implications of using this novel class of agents. This book is an invaluable resource for educators, clinicians, and policy makers who are interested in rejuvenating the field of psychedelic research.” 
-- Stephen Ross, M.D. Assistant Clinical Professor, Psychiatry, NYU School of Medicine Director, Division of Alcoholism and Drug Abuse, Bellevue Hospital Associate Director, Addiction Psychiatry Fellowship, NYU School of Medicine

 

“These volumes present fresh ideas for using psychedelic drugs as therapeutic agents to treat some of the most intractable of psychological ailments. As the authors make clear, the ability of these substances to facilitate direct experiential access to our deepest thoughts, feelings, and spirituality makes them uniquely suited for this purpose. Undoubtedly, their amazing healing potential has yet to be fully realized. Thanks to these forward-thinking educators, researchers, and clinicians, we now have new paths to explore in the cure for old diseases.” -- Nicholas V. Cozzi, Ph.D. Department of Pharmacology University of Wisconsin School of Medicine and Public Health

 

Psychedelic Medicines: New Evidence for Hallucinogenic Substances as Treatments

 

Winkelman, Michael, & Roberts, Thomas B. (editors) (2007).

Westport, CT: Praeger/Greenwood Publishers

Volume I: Psychedelic Medicine: Social, Clinical and Legal Perspectives

 

Preface-Warning. Thomas B. Roberts

Editor’s Overview of Psychedelic Medicines Volume 1.  Michael Winkelman

 

Section I: The Social and Clinical Context

Chapter 1: Therapeutic Bases of Psychedelic Medicines: Psychointegrative Effects.  Michael Winkelman

Chapter 2: The Healing Vine: Ayahuasca as Medicine in the 21st Century. Dennis McKenna

Chapter 3Contemporary Psychedelic Therapy: An Overview. Torsten Passie

Chapter 4: Therapeutic Guidelines: Dangers and Contra-Indications in Therapeutic Applications of Hallucinogens. Ede

            Frecska

 

Section II: Medical Applications

Chapter 5: Response of Cluster Headaches to Psilocybin and LSD. Andrew Sewell & John H. Halpern

Chapter 6: Psilocybin Treatment of Obsessive- Compulsive Disorder. F. A. Moreno & P. L. Delgado

Chapter 7: Therapeutic Uses of MDMA. George Greer & Requa Tolbert

Chapter 8: MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. Michael Mithoefer

Chapter 9: Psychedelic Drugs for the Treatment of Depression. Michael Montagne

Chapter 10: Marijuana and AIDS. Donald Abrams

Chapter 11: The Use of Psilocybin in Patients with Advanced Cancer and Existential Anxiety. C. Grob

 

Section III: Legal Aspects of the Medical Use

Chapter 12: Psychedelic Medicine and the Law.  Richard Boire

Chapter 13: The Legal Bases for Religious Peyote Use. Kevin Feeney

Chapter 14: The Supreme Court’s Psychedelic Case. Alberto Groisman & Marlene de Rios

Chapter 15: Conclusions.  Michael Winkelman & Thomas B. Roberts

 

 

Volume II: Psychedelic Medicine:  Addictions Medicine and Transpersonal Healing

 

PrefaceLancet Editorial

Chapter 1: Introduction — The Adventure Continues. Thomas B. Roberts

 

Section I: Treating Substance Abuse

Chapter 2: Hallucinogens in the Treatment of Alcoholism and Other Addictions.  J. H. Halpern

Chapter 3: Addiction, Despair, and the Soul: Psychedelic Psychotherapy.  R. Yensen & D. Dryer

Chapter 4: The Therapeutic Use of Peyote in the Native American Church.  Joseph Calabrese

Chapter 5: Ibogaine and Substance Abuse Rehabilitation.  Kenneth R. Alper & Howard Lotsof

Chapter 6: Ketamine Psychedelic Psychotherapy.  Evgeny Krupitsky & Eli Kolp

Chapter 7:  Ayahuasca Treatment of Cocaine-Paste Addiction.  Jacques Mabit

 

Section II: Guidelines for Psychotherapeutic Applications

Chapter 8: The Ten Lessons of Psychedelic Psychotherapy… Rediscovered.  Neal Goldsmith

Chapter 9: Therapeutic Guidelines from Shamanic Traditions.  Michael Winkelman

Chapter 10: Common Processes in Psychospiritual Change.  Sean House

Chapter 11: Preliminary Remarks on Interpreting Resistance to Psychedelic Insights.  Dan Merkur

 

Section III: Transpersonal Dimension of Healing with Psychedelic Medicines

Chapter 12: Psychedelics in Psychological Health and Growth.  Roger Walsh & Charles Grob

Chapter 13: Psilocybin Can Occasion Mystical-type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.  R. Griffiths, W. Richards, U. McCann & R. Jesse.

Chapter 14:  Remarkable Healing During Psychedelic Psychotherapy.  Stanislav Grof

Chapter 15: Transpersonal Healing with Hallucinogens.  Roger Marsden & David Lukoff 

Chapter 16: Conclusions and Future Recommendations: The Wider Contexts.  Thomas B. Roberts

Author biographies

Index

 

 

 

List Price: $200.00 0-275-99023-0/978-0-275-99023-Pages:  Publication: 6/30/2007

To order, visit www.greenwood.com, call 1-800-225-5800,